Salud financiera de hoja de balance de Takeda Pharmaceutical

Salud financiera controles de criterios 3/6

Takeda Pharmaceutical tiene un patrimonio de accionistas total de ¥6,742.6B y una deuda total de ¥4,664.2B, lo que sitúa su ratio deuda-patrimonio en 69.2%. Sus activos y pasivos totales son ¥14,222.9B y ¥7,480.3B respectivamente. El BAIT de Takeda Pharmaceutical es de ¥579.2B, por lo que su ratio de cobertura de intereses es de 3.6. Tiene efectivo e inversiones a corto plazo que ascienden a ¥288.4B.

Información clave

69.2%

Ratio deuda-patrimonio

JP¥4.66t

Deuda

Ratio de cobertura de intereses	3.6x
Efectivo	JP¥288.36b
Patrimonio	JP¥6.74t
Total pasivo	JP¥7.48t
Activos totales	JP¥14.22t

Actualizaciones recientes sobre salud financiera

No hay actualizaciones

Recent updates

Takeda: Late-Stage Pipeline Catalysts Approaching, But Vyvanse Patent Expiration Looms

Dec 13

Takeda: Momentum Building Around Core Offerings, Rate Buy

Dec 07

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (¥2,428.8B) de TAK superan a sus pasivos a corto plazo (¥2,282.2B).

Pasivo a largo plazo: Los activos a corto plazo (¥2,428.8B) de TAK no cubren sus pasivos a largo plazo (¥5,198.2B).

Historial y análisis de deuda-patrimonio

Nivel de deuda: La relación deuda neta-capital de TAK (64.9%) se considera alta.

Reducción de la deuda: El ratio deuda-patrimonio de TAK ha pasado de 124.8% a 69.2% en los últimos 5 años.

Cobertura de la deuda: La deuda de TAK no está bien cubierta por el flujo de caja operativo (15.7%).

Cobertura de intereses: Los pagos de intereses de la deuda de TAK están bien cubiertos por el BAIT (3.6x cobertura).

Salud financiera de hoja de balance de Takeda Pharmaceutical

Salud financiera controles de criterios 3/6

Información clave

Actualizaciones recientes sobre salud financiera

Recent updates

Takeda Receives Positive Chmp Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer

U.S. Food and Drug Administration Approves Subcutaneous Administration of Takeda Pharmaceutical Company Limited's ENTYVIO (Vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease

Alinamin Pharmaceutical Co., Ltd. acquired Nihon Pharmaceutical Co., Ltd. from Takeda Pharmaceutical Company Limited (TSE:4502).

Takeda Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2024

Takeda Pharmaceuticals U.S.A, Inc. Announces Approval of Adzynma Intravenous Injection 1500 (Apadamtase Alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura

Takeda Announces U.S. FDA Approval of Supplemental New Drug Application for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL

Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (Tak-079), A Potential Best-In-Class Anti-Cd38 Monoclonal Antibody, for Primary Immune Thrombocytopenia

Takeda Pharmaceutical Company: Attractive Stock But Needs To Grow Net Profits

FDA Approves Takeda's EOHILIA (budesonide Oral Suspension)

Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024

Takeda Pharmaceutical Company Limited Reaffirms Earnings Guidance for the Full Year of Fiscal 2024

Takeda Pharmaceutical Company Limited Announces Chief Financial Officer Succession, Effective April 1, 2024

Takeda's Gammard Liquidid®? Approves by U.S. Fda for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (Cidp)

Takeda Announces U.S. Food and Drug Administration Approves Hyqvia® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase]

Takeda Pharmaceutical Company Limited to Report Q2, 2025 Results on Oct 31, 2024

Takeda Receives Positive Chmp Opinion for Hyqvia as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (Cidp)

The European Commission Approves Label Update for Takhzyro®? (Lanadelumab), Expanding Its Use to A Broader Group of Paediatric Patients with Recurrent Attacks of Hereditary Angioedema (Hae)

U.S. Fda Approves Takeda's Adzynma (Adamts13, Recombinant-Krhn) as the First and Only Recombinant Adamts13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombotic Thrombocytopenic Purpura

Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

Takeda Pharmaceutical Company Limited Announces Late-Breaking Data from Phase 2B Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis At American College of Rheumatology Convergence Annual Meeting

Takeda Pharmaceutical Company Limited Revises Earnings Guidance for the Fiscal Year Ending March 31, 2024

Takeda Pharmaceutical Company Limited Announces Dividend for the Second Quarter Ended September 30, 2023, Payable on December 1, 2023 and Provides Year-End Dividend Guidance for the Year Ending March 31, 2024

Takeda: Why I'm Staying Bearish On This Generic Drug Dividend Play

Takeda Pharmaceutical Company Limited Announces European Commission Approves ADCETRIS (Brentuximab Vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD

Takeda Pharmaceutical Company Limited Announces Phase 3 ADMIRE-CD II Study

Takeda Pharmaceutical Company Limited to Report Q3, 2024 Results on Feb 01, 2024

Takeda Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan

Takeda Pharmaceutical Company Limited Announces U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (Vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis

Takeda Announces Approval of CUVITRU Subcutaneous Immunoglobulin in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent Attacks of Hereditary Angioedema in Patients Aged 2 Years and Older

Takeda Announces FDA Acceptance of NDA Resubmission of Tak-721 (Budesonide Oral Suspension) for the Short-Term Treatment of Eosinophilic Esophagitis

Takeda Pharmaceutical Company Limited Announces FDA Acceptance of BLA for Subcutaneous Administration of ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease

Takeda Announces Positive Topline Results from Phase 2b Study Evaluating TAK-279, a highly selective oral TYK2 Inhibitor, for the Treatment of Active Psoriatic Arthritis

Takeda: Innovative But Volatile, Fairly Priced For The Risk (Downgrade)

Takeda Pharmaceutical Company Limited Provides Earnings Guidance for the Fiscal Year 2023

Takeda Pharmaceutical Company Limited Announces Board Changes

Takeda Presents Full Data Set from Phase 3 ADVANCE-CIDP 1 Clinical Trial Investigating HYQVIA® as a Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting

Takeda: Upside Case Strengthening, Looking To 15x Earnings

HUTCHMED (China) Limited and Takeda Announce Publication of Phase III FRESCO-2 Results in the Lancet

Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency

Takeda Pharmaceutical Company and Eli Lilly and Company Provides Update on Class Action

Takeda Pharmaceutical Company Limited Proposes Dividend

Takeda Pharmaceutical Company Limited to Report Q2, 2024 Results on Oct 26, 2023

Takeda Announces S. Food & Drug Administration Grants Priority Review of TAK-755 for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Takeda Pharmaceutical Company Limited Provides Earnings Guidance for the Fiscal Year 2023

Takeda Pharmaceutical Company Limited Provides Dividend Guidance for the Fiscal Year 2023

Takeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acute Graft-Versus-Host Disease (aGvHD) in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)

Takeda Pharmaceutical Company Limited Announces FDA Approves the Supplemental Biologics License Application for the Expanded Use of TAKHZYRO

Takeda Pharmaceutical Company Limited Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

Takeda Pharmaceutical Company Limited to Report Fiscal Year 2023 Results on May 11, 2023

Takeda Pharmaceutical Q3 Earnings Preview

Takeda’s EXKIVITY® (mobocertinib) Receives Approval from the NMPA of China, Becoming the First and Only Therapy Available for Patients with EGFR Exon20 Insertion+ NSCLC

Takeda's Exkivity gets approval in China for lung cancer subtype

Arrowhead Pharmaceuticals Inc. and Takeda Pharmaceutical Company Limited Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

Takeda Pharmaceutical Company Limited Announces Favorable Phase 3 Safety and Efficacy Results of TAK-755 as Compared to Standard of Care in Congenital Thrombotic Thrombocytopenic Purpura

Takeda’S Phase 3 Aurora Study Provides Evidence of Maribavir’S Clinically Meaningful and Durable Effect in Cytomegalovirus Infection in Hematopoietic Stem Cell Transplant Patients, Despite Missing Primary Endpoint

Takeda: Late-Stage Pipeline Catalysts Approaching, But Vyvanse Patent Expiration Looms

Takeda's Qdenga(R) Dengue Tetravalent Vaccine [Live, Attenuated]) Approves for Use in European Union

Takeda: Momentum Building Around Core Offerings, Rate Buy

Takeda Pharmaceutical Company Limited Announces the U.S. Food and Drug Administration Accept and Grant Priority Review of the Biologics License Application for TAK-003

Takeda Announces Phase 3 Trial of Iclusig (Ponatinib) Met Primary Endpoint in Newly-Diagnosed Ph+ ALL, Setting with No Targeted Treatments Approved in the US

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Descubre empresas con salud financiera